Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

NCT03212404 is registered in ClinicalTrials.gov with Checkpoint Therapeutics, Inc. as lead sponsor.

NCT NCT03212404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03212404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Lead sponsor
Checkpoint Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 20, 2017
Completion date
December 31, 2025
Enrollment
272 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, carcinoma, small cell, classical hodgkin lymphoma, cutaneous squamous cell carcinoma, endometrial cancer, head and neck cancer, lung neoplasms, malignant mesothelioma, advanced, melanoma, merkel cell carcinoma, non hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma